Disclaimer

The alfapump® system is not currently approved in the United States or Canada. In the United States and Canada, the alfapump® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. For more information regarding the POSEIDON clinical study see www.poseidonstudy.com.
The DSR® therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed.
The DSR® therapy is not currently approved for clinical research in the United States or Canada. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe.

Press releases

Sequana Medical announces FDA approval to expand patient enrolment in North American pivotal alfapump® study (POSEIDON)

PRESS RELEASE REGULATED INFORMATION – INSIDE INFORMATION 4 October 2021, 07:00 CET   Completion of patient enrolment expected before end of year Primary endpoint read-out due in Q4 2022 59 patients already recruited in the Pivotal Cohort Ghent, Belgium – 4 October 2021 – Sequana Medical NV (Euronext Brussels: SEQUA, the “Company”), an innovator in...

Sequana Medical to present at 8th Annual HealthTech Investment Forum

Participating in Next Generation Medtech & Device Panel on October 5th, 2021 Ghent, Belgium – 28 September 2021 – Sequana Medical NV (Euronext Brussels: SEQUA, the “Company”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces that Ian Crosbie, Chief Executive Officer, will participate in...

Sequana Medical announces H1 2021 results and provides business update

PRESS RELEASE REGULATED INFORMATION – INSIDE INFORMATION 2 September 2021, 07:00 CET   alfapump® – Positive results from second interim analysis of POSEIDON pivotal study; awaiting FDA approval on POSEIDON pivotal study expansion alfapump® – FDA regulatory submission now expected in mid-2023 due to worldwide supply shortage of electronic components; European commercial activities and clinical...

Sequana Medical appoints Jackie Fielding, former Medtronic VP, to its Board of Directors

  Ghent, Belgium – 31 August 2021 – Sequana Medical NV (Euronext Brussels: SEQUA, the “Company”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces that it has appointed Jackie Fielding, a former Vice President of Medtronic with more than 30 years of experience in...

Sequana Medical Notice of 2021 Half Year Results and Business Update

  Ghent, BELGIUM – 26 August 2021 – Sequana Medical NV (Euronext Brussels: SEQUA, the “Company”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, will announce its half year results ended 30 June 2021 on Thursday, 2 September 2021. The management team will host a conference...

SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES

PRESS RELEASE REGULATED INFORMATION 27 July 2021, 6:00 pm CEST   Ghent, Belgium, 27 July 2021 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, announces in accordance with Article 15 of the Belgian Act...

Sequana Medical’s results from RED DESERT alfapump DSR® study presented as one of the Highlights at Heart Failure 2021 Online Congress

Ghent, BELGIUM – 6 July 2021 – Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces that the positive results from its RED DESERT study of alfapump DSR® (Direct Sodium Removal) which were presented...

Sequana Medical announces positive results from second interim analysis of North American pivotal alfapump® study (POSEIDON)

PRESS RELEASE REGULATED INFORMATION – INSIDE INFORMATION 1 July 2021, 07:00 am CEST   Interim data from 26 patients in the Roll-In Cohort reconfirm positive outcomes against all primary endpoints[i] Over 90% reduction in mean frequency of therapeutic paracentesis versus baseline All patients experienced at least 50% reduction in mean frequency of therapeutic paracentesis per...

Sequana Medical to host a Key Opinion Leader Webinar on “The Impact of Liver Ascites on Patients and Healthcare Systems and the potential of alfapump® therapy in NASH-related ascites”

  Live webinar with Dr. Vargas and Dr. Knuttinen on 15 July 2021 at 4 pm CET  / 10 am ET Ghent, BELGIUM – 17 June 2021 – Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart...

Results from Sequana Medical’s RED DESERT alfapump DSR® study selected for presentation at the Heart Failure 2021 Online Congress

Ghent, BELGIUM – 9 June 2021 – Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces that the abstract on the results from its RED DESERT alfapump DSR (Direct Sodium Removal) study has been...
1 2 3 8

Subscribe to our Press Releases

    I agree to the Sequana Medical Privacy Policy

    We would like to use cookies to better understand your use of this website. This enables us to improve your future experience on our website. Detailed information about the use of cookies on this website and how you can manage or withdraw your consent at any time can be found in our. Privacy & Cookie Policy

    The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

    Close